Navigation Links
Intermittent in Biological Technology
... because atrial fibrillation (AF), a common cardiac
arrythmia, is often intermittent and therefore under diagnosed. Detecting
AF frequently requires more ... to estimate that 20-30% of these subtypes is
likely due to undiagnosed, intermittent AF. This means that AF causes an
even larger proportion of stroke than ...
... AEterna Zentaris. This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing ...
... drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for ...
... study (041) titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study", will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... 2008, the company commenced a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. In early 2009, the company will initiate a Phase I proof-of-mechanism trial in patients with high-grade glioma at Johns Hopkins ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... The unique activity profile of 2NTX-99 suggests potential utility in a range of atherosclerotic, thrombotic, and microvascular diseases, including intermittent claudication, diabetic nephropathy and pulmonary arterial hypertension. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage ...
... and the medical community about blood management as a way to improve the efficiency and quality of care simultaneously." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
... with our mission to provide the best possible service to our client hospitals and optimal outcomes for their patients." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
... pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", involves approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
... a short course therapy with cetrorelix. The improvement lasted well beyond the dosing period. This should, therefore, allow for the development of intermittent dosage regimens of cetrorelix with two or three treatment courses per year, thus relieving concerns about treatment compliance with drugs requiring ...
... two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme. Trial Design Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days ...
... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
... for revenue recognition have now been met. Also includes a $200,000 fee paid by Hollister for marketing rights to our hydorphilic intermittent catheter in September 2003. The fee paid by Hollister was fully recognized in December 2006. This adjustment reduces net income related ...
... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... higher than the estimated efficacious human dose. Clinical trials will begin in 2008 in peripheral vascular disease patients suffering from intermittent claudication and in cancer patients undergoing radiation therapy. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, ...
... AEterna Zentaris. This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing ...
... drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for ...
New Report Just Published: World Prostate Cancer Therapeutics Market Report
... of Orchiectomy II-35 Time to Start Hormonal Therapy II-35 Strategies to Enhance Hormonal Treatment II-36 Combination Therapy II-36 intermittent Therapy II-36 Radiation Therapy II-36 Brachytherapy II-36 Treatment Procedure II-37 Benefits of Brachytherapy II-38 Drawbacks of ...... study (041) titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study", will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... 2008, the company commenced a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. In early 2009, the company will initiate a Phase I proof-of-mechanism trial in patients with high-grade glioma at Johns Hopkins ...
Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... The unique activity profile of 2NTX-99 suggests potential utility in a range of atherosclerotic, thrombotic, and microvascular diseases, including intermittent claudication, diabetic nephropathy and pulmonary arterial hypertension. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage ...
AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
... combination products." AcelRx Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions, with an initial emphasis on pain management. ...New small-scale generator produces alternating current by stretching zinc oxide wires
... Nanotechnology Excellence. Earlier nanowire nanogenerators and microfiber nanogenerators developed by Wang and his research team depended on intermittent contact between vertically-grown zinc oxide nanowires and an electrode, or the mechanical scrubbing of nanowire-covered fibers. These devices were ...... and the medical community about blood management as a way to improve the efficiency and quality of care simultaneously." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
Alexion Reports Third Quarter 2008 Results
... recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis. About Alexion Alexion ...... with our mission to provide the best possible service to our client hospitals and optimal outcomes for their patients." Rising blood costs, intermittent blood shortages and quality of care concerns are encouraging blood centers and hospitals to find more efficient ways to manage blood products. The ...
... pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", involves approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...
Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
... facilities and provide data on its impact on patient care. "Current methods for measuring total hemoglobin are invasive and only offer delayed and intermittent results," stated Joe E. Kiani, Masimo Chairman and CEO. "We look forward to working closely with the first customers of our noninvasive hemoglobin ...Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...Derma Sciences Reports Second Quarter 2008 Results
... ahead. XTRASORB(TM), our new super-absorbent dressing (which complements the MEDIHONEY products) is due out in September, MOBILITY1(TM), our portable intermittent compression device, will be available in October, and we are in the final phase of preparing to launch a novel off-loading device for diabetic foot ...... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
... crystals in and around the connective tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and ...Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...... a short course therapy with cetrorelix. The improvement lasted well beyond the dosing period. This should, therefore, allow for the development of intermittent dosage regimens of cetrorelix with two or three treatment courses per year, thus relieving concerns about treatment compliance with drugs requiring ...
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...... two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme. Trial Design Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days ...
Alexion Reports First Quarter 2008 Results
... recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis. About Alexion ...... proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit ...
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
... in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This ...Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
... specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...Amsterdam Molecular Therapeutics Reports Full Year Results 2007
... - Pre-registration trial in Canada on track - Appointment of Ferdinand Verdonck as chairman of supervisory board. - Global rights for acute intermittent porphyria treatment - Exclusive license to all gene therapy products from CIMA - Agreement with CIMA/Digna Biotech for AAV-mediated IGF-I ...... for revenue recognition have now been met. Also includes a $200,000 fee paid by Hollister for marketing rights to our hydorphilic intermittent catheter in September 2003. The fee paid by Hollister was fully recognized in December 2006. This adjustment reduces net income related ...
Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
... Alexza is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...
Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug ...... higher than the estimated efficacious human dose. Clinical trials will begin in 2008 in peripheral vascular disease patients suffering from intermittent claudication and in cancer patients undergoing radiation therapy. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, ...
Alexza Elects Dr. Hal V. Barron to Its Board of Directors
... is a biopharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic ...Other ContentsOther Tags
(Date:5/21/2013)... world,s largest scientific society, invites news media coverage ... 8-12, 2013, in Indianapolis, Ind. It will take ... area hotels. , With more than 7,100 presentations ... from astronomy to zoology ― the meeting will ... assortment of spot news and feature possibilities. The ...
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... board, The J. M. Smucker Company, and Danny ... Awards yesterday at the GS1 General Assembly and Global ... Mr. Smucker and Mr. Wegman were recognized for their ... Standards - the most broadly used supply chain standards ...
(Date:5/22/2013)... report these findings in the current online edition ... pan-European study could open up new possibilities of ... which tackle diseases before the patient,s nervous system ... group of genetic diseases of the cerebellum and ... have limited control of their muscles. They also ...
(Date:5/22/2013)... new guidelines the first in more than 35 ... for surgical patients. The recommendations, based on a lengthy ... (JHH), can potentially save the medical center more than ... , A report on the research that led up ... Anesthesiology , suggests millions of dollars a year ...
(Date:5/22/2013)... Toppik and Bosley hair fibers, two hair loss concealer products ... hair. Hair loss treatments can be a lengthy process. In ... waiting period, one can use these hair loss concealers. They ... surgery in general. , Bosley and Toppik Hair Thickening ... eliminate the appearance of balding and thinning hair. It is ...
(Date:5/22/2013)... NC (PRWEB) May 22, 2013 The 2013 ... (DSM-5) is the largest change to hit the field ... Jung Center is will help prepare for the release with ... therapists has been trained knowing no other diagnostic scheme besides ... DSM-5 diagnostic manual will be released worldwide. In honor of ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Johns Hopkins rewrites obsolete blood-ordering rules 2Health News:Johns Hopkins rewrites obsolete blood-ordering rules 3Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2[0] Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards[0] A pan-European study: Signs of motor disorders can appear years before disease manifestation[0] Johns Hopkins rewrites obsolete blood-ordering rules[0] TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers[0] What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5
sterolsdaclizumabacceptablewomehaldiSubjectsdependingoccurHuntingtonsCapsulesLiqiangretardsOrderedresection
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |